Search Result

Isoforms Recommended:	ROCK2

Results for "

ROCK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (5) Calcium Channel (5) HIV (3) MMP (1) MNK (1) PKA (6) PKC (7) ROCK (46) SGK (1) Small Interfering RNA (siRNA) (3) STAT (1)
By Research Areas:	Cancer (17) Cardiovascular Disease (13) Inflammation/Immunology (14) Metabolic Disease (2) Neurological Disease (8)

Inhibitors & Agonists

Peptides

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS12117

ROCK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ROCK2 Human Pre-designed siRNA Set A contains three designed siRNAs for ROCK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ROCK2 Human Pre-designed siRNA Set A ROCK2 Human Pre-designed siRNA Set A

HY-RS12118

Rock2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Rock2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rock2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rock2 Mouse Pre-designed siRNA Set A Rock2 Mouse Pre-designed siRNA Set A

HY-RS12119

Rock2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Rock2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Rock2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rock2 Rat Pre-designed siRNA Set A Rock2 Rat Pre-designed siRNA Set A

HY-149700

ROCK2-IN-7	ROCK MMP STAT	Others
ROCK2-IN-7 is a kinase inhibitor targeting to *ROCK2. ROCK2-IN-7 inhibits ROCK2/pSTAT3 Signaling. ROCK2*-IN-7 suppresses systemic immunity activation and attenuates inflammation in psoriasis model .

HY-156592

ROCK2-IN-6

ROCK Inflammation/Immunology

ROCK2-IN-6 (Comp A) is a selective ROCK2 inhibitor, can be used for ROCK mediated diseases, autoimmune diseases and inflammation research .

ROCK2-IN-6	ROCK	Inflammation/Immunology
ROCK2-IN-6 (Comp A) is a selective ROCK2 inhibitor, can be used for ROCK mediated diseases, autoimmune diseases and inflammation research .

HY-156592A

ROCK2-IN-6 hydrochloride	ROCK	Inflammation/Immunology
ROCK2-IN-6 hydrochloride (Comp A) is a selective ROCK2 inhibitor, can be used for ROCK mediated diseases, autoimmune diseases and inflammation research .

HY-103620

ROCK2-IN-2

ROCK Inflammation/Immunology

ROCK2-IN-2 is a selective ROCK2 inhibitor extracted from patent US20180093978A1, Compound A-30, has an IC₅₀ of <1 μM.

ROCK2-IN-2	ROCK	Inflammation/Immunology
ROCK2-IN-2 is a selective *ROCK2* inhibitor extracted from patent US20180093978A1, Compound A-30, has an IC₅₀ of <1 μM.

HY-145294

ROCK2-IN-5	ROCK	Neurological Disease
ROCK2-IN-5 (compound 1d) is a hybrid compound containing structural fragments of the Rho kinase inhibitor fasudil and the NRF2 inducers caffeic and ferulic acids. ROCK2-IN-5 has good multitarget profile and good tolerability. ROCK2-IN-5 has the potential for thr research of Amyotrophic lateral sclerosis (ALS) with a SOD1 mutation .

HY-15307

Belumosudil Maximum Cited Publications 21 Publications Verification KD025; SLx-2119	ROCK	Inflammation/Immunology Cancer
Belumosudil (KD025) is a selective inhibitor of *ROCK2* with IC₅₀s of 105 nM and 24 µM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .

HY-15307A

Belumosudil mesylate Maximum Cited Publications 21 Publications Verification KD025 mesylate; SLx-2119 mesylate	ROCK	Inflammation/Immunology
Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of *ROCK2* with IC₅₀s of 105 nM and 24 µM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .

HY-10833

ROCK-IN-10	ROCK	Cardiovascular Disease
ROCK-IN-10 (compound 50) is a potent *ROCK* inhibitor with IC₅₀ values of 6 nM and 4 nM for ROCK1 and ROCK2, respectively. ROCK-IN-10 shows >100-fold selectivity against other kinases .

HY-15687

SAR407899 hydrochloride 2 Publications Verification	ROCK	Metabolic Disease
SAR407899 hydrochloride is a selective, potent and ATP-competitive *ROCK* inhibitor, with an IC₅₀ of 135 nM for *ROCK-2, and K_is of 36 nM and 41 nM for human and rat ROCK-2*, respectively.

HY-149266

THK01	ROCK	Cancer
THK01 is a potent *ROCK2* inhibitor with IC₅₀ values of 5.7 and 923 nM for ROCK2 and ROCK1, respectively. THK01 inhibits breast cancer metastasis through the ROCK2-STAT3 signaling pathway. THK01 can be used in research of breast cancer .

HY-15687A

SAR407899 2 Publications Verification	ROCK	Metabolic Disease
SAR407899 is a selective, potent and ATP-competitive *ROCK* inhibitor, with an IC₅₀ of 135 nM for *ROCK-2, and K_is of 36 nM and 41 nM for human and rat ROCK-2*, respectively. SAR407899 shows stable inhibition of migrasome formation.

HY-12659

LX7101 2 Publications Verification	ROCK	Others
LX7101 is a potent inhibitor of LIMK and *ROCK2* with IC₅₀ values of 24, 1.6 and 10 nM for LIMK1, LIMK2 and ROCK2, respectively; also inhibits PKA with an IC₅₀ less than 1 nM.

HY-15556

GSK269962A 2 Publications Verification GSK 269962	ROCK	Cardiovascular Disease Inflammation/Immunology
GSK269962A (GSK 269962) is a potent *ROCK* inhibitor with IC₅₀s of 1.6 and 4 nM for recombinant human *ROCK1* and *ROCK2* respectively. GSK269962A has anti-inflammatory and vasodilatory activities .

HY-15556A

GSK269962A hydrochloride GSK 269962 hydrochloride	ROCK	Cardiovascular Disease Inflammation/Immunology
GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent *ROCK* inhibitor with IC₅₀s of 1.6 and 4 nM for recombinant human *ROCK1* and *ROCK2* respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities .

HY-U00351

ROCK-IN-1

1 Publications Verification

ROCK Cardiovascular Disease Inflammation/Immunology

ROCK-IN-1 is a potent inhibitor of ROCK, with an IC₅₀ of 1.2 nM for ROCK2.
HY-148808

Zelasudil

RXC007
ROCK Others

Zelasudil is a Rho-associated (ROCK) kinase inhibitor. Zelasudil has a ROCK2 binding affinity ^[2].

ROCK-IN-1 1 Publications Verification	ROCK	Cardiovascular Disease Inflammation/Immunology
ROCK-IN-1 is a potent inhibitor of *ROCK, with an IC₅₀* of 1.2 nM for ROCK2.

Zelasudil RXC007	ROCK	Others
Zelasudil is a *Rho-associated (ROCK) kinase* inhibitor. Zelasudil has a *ROCK2* binding affinity ^[2].

HY-15720A

H-1152 dihydrochloride 1 Publications Verification	ROCK	Neurological Disease
H-1152 dihydrochloride is a membrane-permeable and selective *ROCK* inhibitor, with a K_i value of 1.6 nM, and an IC₅₀ value of 12 nM for *ROCK2*.

HY-13911

Hydroxyfasudil 3 Publications Verification HA-1100	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
Hydroxyfasudil is a *ROCK* inhibitor, with IC₅₀s of 0.73 and 0.72 μM for *ROCK1* and *ROCK2*, respectively.

HY-13911A

Hydroxyfasudil hydrochloride 3 Publications Verification HA-1100 hydrochloride; HA 1100 hydrochloride; HA1100 hydrochloride	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
Hydroxyfasudil hydrochloride is a *ROCK* inhibitor, with IC₅₀s of 0.73 and 0.72 μM for *ROCK1* and *ROCK2*, respectively.

HY-15720

H-1152 1 Publications Verification	ROCK	Neurological Disease
H-1152 is a membrane-permeable and selective *ROCK* inhibitor, with a K_i value of 1.6 nM, and an IC₅₀ value of 12 nM for *ROCK2*.

HY-15685

Ripasudil 5 Publications Verification K-115	ROCK	Neurological Disease
Ripasudil (K-115) is a specific inhibitor of *ROCK, with IC₅₀s of 19 and 51 nM for ROCK2* and *ROCK1*, respectively.

HY-15755

RKI-1447

2 Publications Verification

ROCK Cancer

RKI-1447 is a potent small molecule inhibitor of ROCK1 and ROCK2 with IC₅₀ values of 14.5 nM and 6.2 nM, respectively.

RKI-1447 2 Publications Verification	ROCK	Cancer
RKI-1447 is a potent small molecule inhibitor of *ROCK1* and *ROCK2* with IC₅₀ values of 14.5 nM and 6.2 nM, respectively.

HY-119937

ROCK inhibitor-2 2 Publications Verification	ROCK	Cardiovascular Disease Inflammation/Immunology
ROCK inhibitor-2 is a selective dual *ROCK1* and *ROCK2* inhibitor with IC₅₀s of 17 nM and 2 nM, respectively .

HY-10319

BAY-549 2 Publications Verification ROCK-IN-2; Azaindole 1; TC-S 7001	ROCK	Cardiovascular Disease
BAY-549 (Azaindole 1) is an orally active and ATP-competitive *ROCK* inhibitor with IC₅₀s of 0.6 and 1.1 nM for human *ROCK-1* and *ROCK-2*, respectively .

HY-15685A

Ripasudil free base K-115 free base	ROCK	Neurological Disease
Ripasudil free base (K-115 free base) is a specific inhibitor of *ROCK, with IC₅₀s of 19 and 51 nM for ROCK2* and *ROCK1*, respectively.

HY-113641

ROCK-IN-32	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
ROCK-IN-32 is a *ROCK* inhibitor, with an IC₅₀ value of 11 nM for *ROCK2. ROCK*-IN-32 can be used in research of cardiovascular disease, cancer and inflammation .

HY-12437

BDP5290

ROCK Cancer

BDP5290 is a potent inhibitor of both ROCK and MRCK with IC₅₀s of 5 nM, 50 nM, 10 nM and 100 nM for ROCK1, ROCK2, MRCKα and MRCKβ, respectively.

BDP5290	ROCK	Cancer
BDP5290 is a potent inhibitor of both *ROCK* and MRCK with IC₅₀s of 5 nM, 50 nM, 10 nM and 100 nM for *ROCK1, ROCK2, MRCKα* and MRCKβ, respectively.

HY-108518

SB-772077B dihydrochloride	ROCK	Cardiovascular Disease
SB-772077B dihydrochloride is an aminofurazan-based Rho kinase (ROCK) inhibitor with IC₅₀s of 5.6 nM and 6 nM toward ROCK1 and ROCK2, respevtively .

HY-100270

Rho-Kinase-IN-1	ROCK	Cancer
Rho-Kinase-IN-1 is a Rho kinase (ROCK) inhibitor (K_i values of 30.5 and 3.9 nM for ROCK1 and ROCK2, respectively) extracted from US20090325960A1, compound 1.008 .

HY-110339

RKI-1447 dihydrochloride 2 Publications Verification	ROCK Apoptosis	Cancer
RKI 1447 dihydrochloride is a potent and selective *ROCK* inhibitor with IC₅₀s of 14.5 and 6.2 nM for *ROCK1* and *ROCK2, respectively . RKI 1447 dihydrochloride suppresses colorectal carcinoma cell growth and promotes apoptosis* ^[2].

HY-122011

PF-4950834	ROCK SGK PKA PKC	Inflammation/Immunology
PF-4950834 is a potent, selective, orally bioavailable, ATP-competitive rho kinase inhibitor with IC₅₀ values of 8.35 nM and 33.12 nM against ROCK2 and ROCK1, respectively. PF-4950834 inhibits neutrophil migration .

HY-126275

HSD1590	ROCK	Cancer
HSD1590 is potent *ROCK* inhibitor, with IC₅₀s of 1.22 and 0.51 nM for ROCK1 and ROCK2, respectively. HSD1590 exhibits single digit nanomolar binding to ROCK (K_ds<2 nM). HSD1590 displays low cytotoxicity .

HY-16758

Verosudil AR-12286	ROCK	Neurological Disease
Verosudil (AR-12286) is a potent, selective Rho-kinase (ROCK) inhibitor with K_is of 2 and 2 nM for ROCK1 and ROCK2, respectively. AR-12286 lowers intraocular pressure (IOP) primarily by increasing aqueous humour outflow through the trabecular meshwork ^[2].

HY-150640

Rho-Kinase-IN-2	ROCK	Neurological Disease
Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC₅₀=3 nM). Rho-Kinase-IN-2 can be used in Huntington’s research .

HY-15392

Chroman 1 15+ Cited Publications	ROCK	Cardiovascular Disease
Chroman 1 is a highly potent and selective *ROCK* inhibitor. Chroman 1 is more potent against ROCK2 (IC₅₀=1 pM) than ROCK1 (IC₅₀=52 pM). Chroman 1 also has inhibitory activity against MRCK, with an IC₅₀ of 150 nM ^[2].

HY-15392A

Chroman 1 dihydrochloride 15+ Cited Publications	ROCK	Cardiovascular Disease
Chroman 1 dihydrochloride is a highly potent and selective *ROCK* inhibitor. Chroman 1 dihydrochloride is more potent against ROCK2 (IC₅₀=1 pM) than ROCK1 (IC₅₀=52 pM). Chroman 1 dihydrochloride also has inhibitory activity against MRCK, with an IC₅₀ of 150 nM ^[2].

HY-103045

CMPD101 3 Publications Verification	PKC ROCK	Cardiovascular Disease
CMPD101 is a potent, highly selective and membrane-permeable small-molecule inhibitor of *GRK2/3* with IC₅₀ of 18 nM and 5.4 nM, respectively. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC₅₀s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively. CMPD101 can be used for the study of heart failure .

HY-10341

Fasudil Hydrochloride 10+ Cited Publications HA-1077 Hydrochloride; AT-877 Hydrochloride	ROCK Calcium Channel Autophagy PKA PKC HIV	Cancer
Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil Hydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator ^[2] .

HY-10341A

Fasudil HA-1077; AT877	ROCK Calcium Channel Autophagy PKA PKC	Cancer
Fasudil (HA-1077; AT877) is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil is also a potent Ca ²⁺ channel antagonist and vasodilator ^[2] .

HY-10341C

Fasudil dihydrochloride HA-1077 dihydrochloride; AT-877 dihydrochloride	Calcium Channel ROCK PKA PKC Autophagy HIV	Cancer
Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil dihydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator ^[2] .

HY-10341B

Fasudil hydrochloride semihydrate HA-1077 hydrochloride semihydrate; AT877 hydrochloride semihydrate	ROCK Calcium Channel Autophagy HIV PKA PKC	Cancer
Fasudil (HA-1077; AT877) hydrochloride semihydrate is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil hydrochloride semihydrate is also a potent Ca ²⁺ channel antagonist and vasodilator ^[2] .

HY-10341D

Fasudil mesylate HA-1077 mesylate; AT-877 mesylate	ROCK Calcium Channel Autophagy PKA PKC	Cancer
Fasudil (HA-1077; AT877) mesylate is a nonspecific and orally active *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil mesylate is also a potent Ca ²⁺ channel antagonist and vasodilator ^[2] .

HY-153564

ROCK-IN-6	ROCK	Inflammation/Immunology
ROCK-IN-6 is a potent and selectiveROCK2 inhibitor with an IC₅₀ of 2.19 nM. ROCK-IN-6 is extracted from patent WO2021164351 A1, example 7, has the potential for glaucoma and retinal diseases research .

HY-124638

MNK inhibitor 9	MNK	Cancer
MNK inhibitor 9 is a potent and selective inhibitor of *MNK1/2* with IC₅₀ values of 0.003 µM and 0.003 µM for MNK1 and *MNK2* respectively. MNK inhibitor 9 has good cell permeability. MNK inhibitor 9 can be used in tumor related research .

HY-107209

RKI-1313	ROCK	Cancer
RKI-1313 is a *ROCK* inhibitor with IC₅₀s of 34, 8 µM for ROCK 1 and ROCK 2, respectively. RKI-1313 shows little effect on the phosphorylation levels of ROCK substrates, migration, invasion or anchorage-independent growth .

HY-109191

Sovesudil PHP-201; AMA0076	ROCK	Others
Sovesudil (PHP-201) is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC₅₀s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil lowers intraocular pressure (IOP) without inducing hyperemia ^[2].

HY-109191A

Sovesudil hydrochloride PHP-201 hydrochloride; AMA0076 hydrochloride	ROCK	Neurological Disease
Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive, locally acting Rho kinase *(ROCK)* inhibitor with IC₅₀s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil hydrochloride lowers intraocular pressure (IOP) without inducing hyperemia ^[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: